APGE 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
APGE 近期報酬表現
0.57%
Apogee therapeutics inc
-1.45%
同產業平均
0.16%
S&P500
與 APGE 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
APM | Aptorum group ltd | 2 分 | 3 分 | 2 分 | - | 1 分 | |
LTRN | Lantern pharma inc | 3 分 | 5 分 | 4 分 | 1 分 | 1 分 | |
MNMD | Mind medicine (mindmed) inc | 1 分 | 3 分 | 3 分 | 1 分 | 1 分 | |
PHGE.U | Biomx inc | 2 分 | 3 分 | - | - | 1 分 | |
CRGX | Cargo therapeutics inc | - | 2 分 | 2 分 | 3 分 | 1 分 |
- APM Aptorum group ltd價值 2 分趨勢 3 分波段 2 分籌碼 -股利 1 分查看更多
APGE 公司資訊
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4R?. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.